Monopar's Q2 Net Loss Narrows to $81,932 Amidst Reverse Stock Split

TL;DR

**Monopar's Q2 loss narrowed, but with zero revenue and a recent reverse split, it's still a high-risk bet on future drug development.**

AI Summary

Monopar Therapeutics reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage as a pharmaceutical company. The net loss for the three months ended June 30, 2025, was $6,127,457, compared to a net loss of $6,102,560 for the same period in 2024, representing a slight increase in loss. For the six months ended June 30, 2025, the net loss was $81,932, a significant reduction from the $754,939 net loss reported for the six months ended June 30, 2024. Key business changes include the retroactive effect of a 1-for-5 reverse stock split on August 12, 2024, impacting share and per-share data. The company's cash equivalents as of June 30, 2025, primarily consist of investments in money market accounts and U.S. Treasury securities. Strategic outlook remains focused on drug development, with ongoing share-based payment arrangements for employees, including 225,881 options with various vesting schedules. The company continues to manage its capital structure, with 40,000,000 shares authorized for common stock as of June 30, 2025.

Why It Matters

For investors, Monopar's continued net losses, despite a significant reduction in the six-month period, highlight the inherent risks of pre-revenue biotech investments. The 1-for-5 reverse stock split on August 12, 2024, aimed to boost share price and maintain listing compliance, but its long-term impact on investor confidence and liquidity remains to be seen. Employees are directly affected by the share-based payment arrangements, with 225,881 options vesting over various periods, tying their incentives to future company performance. Customers, primarily future patients, are not yet directly impacted as the company remains in the drug development phase. In the competitive pharmaceutical landscape, Monopar's ability to advance its pipeline and secure future funding will be critical to its survival and potential market entry.

Risk Assessment

Risk Level: high — Monopar Therapeutics is a pre-revenue company, reporting no revenue for the three and six months ended June 30, 2025, which inherently carries high risk. The company also reported a net loss of $6,127,457 for the three months ended June 30, 2025, indicating ongoing cash burn. Furthermore, the 1-for-5 reverse stock split on August 12, 2024, often signals underlying financial distress or a need to meet exchange listing requirements, adding to investor uncertainty.

Analyst Insight

Investors should approach MNPR with extreme caution, recognizing it as a speculative investment in a pre-revenue biotech. Monitor future clinical trial progress and cash burn rates closely, as the company's viability hinges on successful drug development and subsequent commercialization or partnerships.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$6,127,457

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $0 — Revenue (No revenue reported for Q2 2025, indicating pre-commercial stage.)
• -$6.13M — Net Loss (Q2 2025) (Increased slightly from -$6.10M in Q2 2024.)
• -$81.9K — Net Loss (YTD Q2 2025) (Significantly reduced from -$754.9K in YTD Q2 2024.)
• 1-for-5 — Reverse Stock Split Ratio (Effective August 12, 2024, impacting share data.)
• 225,881 — Employee Stock Options (Granted with various vesting schedules.)
• 40,000,000 — Authorized Common Shares (As of June 30, 2025.)

Key Players & Entities

• Monopar Therapeutics Inc. (company) — filer of the 10-Q
• 03 Life Sciences (company) — organization name associated with the filer
• $6,127,457 (dollar_amount) — net loss for the three months ended June 30, 2025
• $6,102,560 (dollar_amount) — net loss for the three months ended June 30, 2024
• $81,932 (dollar_amount) — net loss for the six months ended June 30, 2025
• $754,939 (dollar_amount) — net loss for the six months ended June 30, 2024
• August 12, 2024 (date) — effective date of the 1-for-5 reverse stock split
• 225,881 (dollar_amount) — number of employee stock options granted
• 40,000,000 (dollar_amount) — authorized shares of common stock as of June 30, 2025
• June 30, 2025 (date) — end of the reporting period for the 10-Q

FAQ

Risk Factors

• Pre-Commercial Stage Burn Rate [high — financial]: Monopar Therapeutics reported a net loss of $6,127,457 for Q2 2025, a slight increase from $6,102,560 in Q2 2024. This sustained high burn rate is typical for pre-commercial pharmaceutical companies but poses a significant financial risk if development timelines are extended or funding is not secured.
• Drug Development Uncertainty [high — operational]: As a pharmaceutical company focused on drug development, Monopar Therapeutics faces inherent risks associated with clinical trials, regulatory approvals, and market adoption. The success of its pipeline candidates is critical for future revenue generation.
• Reliance on Future Funding [high — financial]: The company's financial statements indicate no revenue, meaning it relies on existing cash reserves and potentially future financing rounds to fund its operations and development activities. A lack of sufficient capital could impede progress.
• Regulatory Approval Process [high — regulatory]: Gaining approval from regulatory bodies like the FDA is a lengthy, complex, and expensive process. Delays or failures in obtaining these approvals can significantly impact the company's timeline and financial viability.
• Impact of Reverse Stock Split [medium — financial]: The 1-for-5 reverse stock split effective August 12, 2024, while intended to improve share price perception, can sometimes be viewed negatively by investors if not accompanied by fundamental improvements. It also impacts historical per-share data.

Industry Context

The pharmaceutical industry is characterized by high R&D costs, lengthy development cycles, and stringent regulatory hurdles. Companies like Monopar Therapeutics operate in a competitive landscape where innovation and successful clinical outcomes are paramount. The sector is driven by the need for novel therapies and faces constant pressure from payers and healthcare systems to demonstrate value.

Regulatory Implications

Monopar Therapeutics is subject to the rigorous regulatory approval processes of agencies like the FDA. Failure to meet safety and efficacy standards or navigate complex regulatory pathways can lead to significant delays, increased costs, or outright rejection of drug candidates, posing a substantial risk to the company's future.

What Investors Should Do

1. Monitor cash burn rate and runway.
2. Evaluate progress in drug development pipeline.
3. Assess the impact of the reverse stock split.

Key Dates

• 2024-08-12: Reverse Stock Split — A 1-for-5 reverse stock split was effective, impacting share count and per-share data retroactively. This can affect investor perception and trading liquidity.
• 2025-06-30: End of Q2 2025 — The reporting period for the 10-Q filing. Key financial metrics like net loss and cash position are reported as of this date.

Glossary

Pre-commercial stage

A phase in a pharmaceutical company's lifecycle where it has not yet received regulatory approval for its drugs and therefore has no product sales revenue. (Explains why Monopar Therapeutics has $0 revenue and incurs net losses.)

Reverse Stock Split

A corporate action where a company reduces the total number of its outstanding shares by consolidating existing shares into fewer, proportionally more valuable shares. (Monopar Therapeutics implemented a 1-for-5 reverse stock split, affecting share counts and per-share metrics.)

Cash Equivalents

Short-term, highly liquid investments that are readily convertible to known amounts of cash and which are so near to their maturity that they present an insignificant risk of changes in value because of changes in interest rates. (Monopar Therapeutics holds its cash in money market accounts and U.S. Treasury securities, indicating a conservative approach to managing its liquid assets.)

Share-based Payment Arrangement

A transaction in which a company receives goods or services (typically from employees) in exchange for equity instruments or awards based on equity. (Monopar Therapeutics has outstanding employee stock options, which are accounted for under these arrangements.)

Year-Over-Year Comparison

Monopar Therapeutics reported no revenue in the current period, consistent with its pre-commercial status, mirroring the prior year. The net loss for the three months ended June 30, 2025, saw a slight increase to $6,127,457 from $6,102,560 in the same period of 2024. However, the year-to-date net loss significantly decreased from $754,939 in the first six months of 2024 to $81,932 in the first six months of 2025, indicating improved cost management or timing of expenses over the longer period. The company also retroactively applied a 1-for-5 reverse stock split, impacting share data comparability.

Key Financial Figures

• $0.001 — e on which registered Common Stock, $0.001 par value MNPR The Nasdaq Stock Mar

Filing Documents

• mnpr20250630_10q.htm (10-Q) — 997KB
• ex_828981.htm (EX-31.1) — 13KB
• ex_828982.htm (EX-31.2) — 13KB
• ex_828983.htm (EX-32.1) — 8KB
• pipelinechart71825.jpg (GRAPHIC) — 52KB
• 0001437749-25-026042.txt ( ) — 5350KB
• mnpr-20250630.xsd (EX-101.SCH) — 46KB
• mnpr-20250630_cal.xml (EX-101.CAL) — 26KB
• mnpr-20250630_def.xml (EX-101.DEF) — 320KB
• mnpr-20250630_lab.xml (EX-101.LAB) — 292KB
• mnpr-20250630_pre.xml (EX-101.PRE) — 342KB
• mnpr20250630_10q_htm.xml (XML) — 826KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 7 Condensed Consolidated Balance Sheets as of June 30, 2025, and December 31, 2024 7 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2025 and 2024 8 Condensed Consolidated Statements of Stockholders' Equity for the Three and Six Months Ended June 30, 2025 and 2024 9 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 11 Notes to Condensed Consolidated Financial Statements 12 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 24 Item 4.

Controls and Procedures

Controls and Procedures 33 Part II OTHER INFORMATION 33 Item 1A.

Risk Factors

Risk Factors 33 Item 5. Other Information 33 Item 6. Exhibits 34

Signatures

Signatures 35 2 Table of Contents

Forward-Looking Statements

Forward-Looking Statements This Quarterly Report on Form 10-Q contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Act"), and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts included in this Quarterly Report on Form 10-Q are forward-looking statements. The words "hopes," "believes," "anticipates," "plans," "seeks," "estimates," "projects," "expects," "intends," "may," "could," "should," "would," "will," "continue," and similar expressions are intended to identify forward-looking statements. The following uncertainties and factors, among others, could affect future performance and cause actual results to differ materially from those matters expressed in or implied by forward-looking statements: our ability to raise sufficient funds in order for us to support continued clinical, regulatory and commercial development of our programs and to make contractual future milestone payments, as well as our ability to further raise additional funds in the future to support any existing or future product candidate programs through completion of clinical trials, the approval processes and, if applicable, commercialization our ability to raise funds on acceptable terms our ability to find a suitable pharmaceutical partner or partners to further our development efforts, under acceptable financial terms risks and uncertainties associated with our or any development partners' research and development activities, including preclinical studies, clinical trials, regulatory submissions, and manufacturing and quality expenses known and unknown risks associated with developing copper-chelating therapies and radiopharmaceutical therapeutics and imaging agents the uncertainty of timeframes for our clinical trials and regulatory reviews for approval to market products uncertainties related to the regulatory discussions we may initiate related to A

Financial Statements

Item 1. Financial Statements Monopar Therapeutics Inc. Condensed Consolidated Balance Sheets (Unaudited) June 30, 2025 December 31, 2024* Assets Current assets: Cash and cash equivalents $ 39,501,936 $ 45,816,289 Investments 13,748,473 14,395,913 Other current assets 497,294 78,869 Total current assets 53,747,703 60,291,071 Operating lease right-of-use asset 118,170 — Total assets $ 53,865,873 $ 60,291,071 Liabilities and Stockholders' Equity Current liabilities: Accounts payable, accrued expenses and other current liabilities $ 1,583,613 $ 2,254,300 In-process R&D accrued expenses — 3,000,000 Total current liabilities 1,583,613 5,254,300 Non-current operating lease liability 80,366 — Total liabilities 1,663,979 5,254,300 Commitments and contingencies (Note 8) Stockholders' equity: Common stock, par value of $ 0.001 per share, 40,000,000 shares authorized, 6,127,457 and 6,102,560 shares issued and outstanding at June 30, 2025, and December 31, 2024, respectively** 6,127 6,103 Additional paid-in capital 132,989,324 130,787,312 Accumulated other comprehensive income 77,577 35,992 Accumulated deficit ( 80,871,134 ) ( 75,792,636 ) Total stockholders' equity 52,201,894 55,036,771 Total liabilities and stockholders' equity $ 53,865,873 $ 60,291,071 * Derived from the Company's audited consolidated financial statements. ** Information pertaining to the number of shares outstanding gives retroactive effect to a 1 for 5 reverse stock split that became effective on August 12, 2024. The accompanying notes are an integral part of these condensed consolidated financial statements. 7 Table of Contents Monopar Therapeutics Inc. Condensed Consolidated (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 1,730,000 $ 1,130,978 $ 3,373,375 $ 2,097,088 Gener

View Full Filing

View this 10-Q filing on SEC EDGAR